Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Labopharm, Gruppo Angelini Collaborate To Commercialise Oleptro In US
As part of the joint venture agreement, Labopharm is expected to grant Angelini Labopharm the exclusive right to market and sell Oleptro in the US. The joint venture,
As part of the joint venture agreement, Labopharm is expected to grant Angelini Labopharm the exclusive right to market and sell Oleptro in the US. The joint venture,
In a double-blind, active-controlled Phase II study of 480 randomised subjects, the safety, tolerability and immunogenicity of a single 15microgram dose or 60microgram dose (per strain) of trivalent
KRN5500 is a non-opioid analgesic agent, a semi-synthetic derivative of spicamycin: (6-[4-Deoxy-4-[(2E,4E)-tetradecadienoylglycyl]amino-L-glycero-B-L-manno-heptopyranosyl]amino-9H-purine). As per the terms of the collaboration, NCI is expected to fund the studies and Dara
Discovered by Takeda, Azilsartan medoxomil is designed to lower blood pressure by blocking the action of a vasopressor hormone, angiotensin II. Takeda Pharmaceutical said that the NDA submission
AstraZeneca signed a civil settlement to resolve allegations that by marketing Seroquel for unapproved uses, the company caused false claims for payment to be submitted to federal insurance
Mantrax facilitates alliances between India, Japan and Australia, particularly in high technology areas, through sourcing from contract research and manufacturing organisations, licensing of intellectual property and value-adding to
The agreements also settle all litigation between Synergetics and Alcon. As provided by the settlement and license agreement and supply agreement, Alcon is expected to pay Synergetics approximately
ChronTech Pharma said that at follow-up of the ChronVac-C -study where patients now have started treatment according to standard-of-care (interferon and ribavirin) all patients (100%) were virus free
Seattle Genetics has posted a net income of $11.46m for the first quarter 2010, or $0.11 per diluted share, compared to net loss of $27.26m, or $0.33 per
As per the terms of the agreement Pepscan is expected to receive an undisclosed cash payment as well as a minority interest in Immunovo. Wim Mol, CEO of